- Show all
- Alicaforsen - review papers
- Alicaforsen - treatment case series papers
- Alicaforsen - Phase 2 Data
- Antisense
- Inflammatory Bowel Disease
- ICAM-1
- Renzapride - Irritable Bowel Syndrome Phase 2 Data
- Renzapride - Irritable Bowel Syndrome Phase 3 Data
- Renzapride in Systemic Scleroderma - Overall Disease Pathology
- Renzapride in Systemic Scleroderma - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Therapeutic Effect of "Prides"
- Renzapride in Gastroparesis Phase 2 Data
Clinical trial: Renzapride therapy for constipation-predominant irritable bowel syndrome– multicenter, randomized, placebo-controlled, double-blind study in primary healthcare setting
Renzapride - Irritable Bowel Syndrome Phase 2 Data
George AM, Meyers NL & Hickling RI. (2008)
Aliment Pharmacol Ther; 27: 830–7
Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome
Renzapride - Irritable Bowel Syndrome Phase 2 Data
Tack, J., Middleton, S. J., Horne, M. C., Piessevaux, H., Bloor, J. S., Meyers, N. L., & Palmer, R. M. J. (2006)
Alimentary Pharmacology and Therapeutics, 23(11), 1655–1665
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome
Renzapride - Irritable Bowel Syndrome Phase 2 Data
Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D & Thomforde, G. (2004)
Clin Gastroenterol Hepatol; 2: 895–904
Disclaimer
The information in “published papers” is provided by Atlantic Healthcare plc, and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.